| Quetiapine for insomnia: a review of the literature SL Anderson, JP Vande Griend American journal of health-system pharmacy 71 (5), 394-402, 2014 | 150 | 2014 |
| Effects of medical marijuana on migraine headache frequency in an adult population DN Rhyne, SL Anderson, M Gedde, LM Borgelt Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36 (5 …, 2016 | 126 | 2016 |
| Histamine-1 receptor antagonism for treatment of insomnia JPV Griend, SL Anderson Journal of the American Pharmacists Association 52 (6), e210-e219, 2012 | 103 | 2012 |
| Association of pancreatitis with glucagon-like peptide-1 agonist use SL Anderson, JM Trujillo Annals of Pharmacotherapy 44 (5), 904-909, 2010 | 103 | 2010 |
| Suvorexant in insomnia: efficacy, safety and place in therapy DN Rhyne, SL Anderson Therapeutic advances in drug safety 6 (5), 189-195, 2015 | 89 | 2015 |
| Chemical basis of the sulfophospho-vanillin reaction for estimating total serum lipid A Joseph, M Knight, S Anderson, M James, H Rawie Clinical Chemistry 18 (3), 198-201, 1972 | 77 | 1972 |
| A review of the role of the pharmacist in heart failure transition of care SL Anderson, JC Marrs Advances in therapy 35, 311-323, 2018 | 76 | 2018 |
| Novel class of medications, orexin receptor antagonists, in the treatment of insomnia–critical appraisal of suvorexant JL Norman, SL Anderson Nature and science of sleep, 239-247, 2016 | 71 | 2016 |
| Dapagliflozin efficacy and safety: a perspective review SL Anderson Therapeutic advances in drug safety 5 (6), 242-254, 2014 | 66 | 2014 |
| Oral semaglutide in type 2 diabetes SL Anderson, TR Beutel, JM Trujillo Journal of Diabetes and its Complications 34 (4), 107520, 2020 | 57 | 2020 |
| Dapagliflozin for the treatment of type 2 diabetes SL Anderson, JC Marrs Annals of Pharmacotherapy 46 (4), 590-598, 2012 | 52 | 2012 |
| Basal insulin use with GLP-1 receptor agonists SL Anderson, JM Trujillo Diabetes Spectrum 29 (3), 152-160, 2016 | 45 | 2016 |
| Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness SL Anderson, JM Trujillo Therapeutic advances in chronic disease 7 (1), 4-17, 2016 | 37 | 2016 |
| Implementation of a clinical pharmacy specialist-managed telephonic hospital discharge follow-up program in a patient-centered medical home SL Anderson, JC Marrs, JP Vande Griend, R Hanratty Population health management 16 (4), 235-241, 2013 | 37 | 2013 |
| Determining predictors of response to exenatide in type 2 diabetes SL Anderson, JM Trujillo, M McDermott, JJ Saseen Journal of the American Pharmacists Association 52 (4), 466-471, 2012 | 35 | 2012 |
| Bempedoic acid for the treatment of dyslipidemia JC Marrs, SL Anderson Drugs in context 9, 2020 | 30 | 2020 |
| Role of clinical pharmacists and pharmacy support personnel in transitions of care PM Stranges, CA Jackevicius, SL Anderson, DS Bondi, I Danelich, ... Journal of the American College of Clinical Pharmacy 3 (2), 532-545, 2020 | 29 | 2020 |
| Once-weekly albiglutide in the management of type 2 diabetes: patient considerations HN Woodward, SL Anderson Patient preference and adherence, 789-803, 2014 | 24 | 2014 |
| Prevalence of and factors that influence board certification among pharmacy practice faculty at United States colleges and schools of pharmacy KA Toussaint, K Watson, JC Marrs, DA Sturpe, SL Anderson, ST Haines Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33 (1 …, 2013 | 20 | 2013 |
| Ertugliflozin in the treatment of type 2 diabetes mellitus JC Marrs, SL Anderson Drugs in Context 9, 2020 | 17 | 2020 |
Joel C. MarrsProfessor, University of Tennessee Health Science Center在 uthsc.edu 的电子邮件经过验证
